A retrospective study on the transition of radiation dose rate and iodine distribution in patients with I-131-treated well-differentiated thyroid cancer to improve bed control shorten isolation periods

  title={A retrospective study on the transition of radiation dose rate and iodine distribution in patients with I-131-treated well-differentiated thyroid cancer to improve bed control shorten isolation periods},
  author={Naoya Yama and Koh-Ichi Sakata and Hideki Hyodoh and Mitsuharu Tamakawa and Masato Hareyama},
  journal={Annals of Nuclear Medicine},
ObjectiveTo evaluate for how long patients should be isolated after I-131 treatment for thyroid cancer according to the guidelines issued by the Japanese Ministry of Welfare.MethodsWe reviewed 92 therapies performed in 76 patients who were administered I-131 at our hospital from July 2007 to September 2009. Fifty-six patients were given 2220 or 2960 MBq I-131 at the first therapy, and 29 patients underwent 36 repeated therapies using 2960, 3700, 5550 or 7400 MBq I-131. We surveyed radioactivity… Expand
2 Citations
Radiation dose rates of differentiated thyroid cancer patients after 131I therapy
Investigation of radiation dose rates in 131I-treated DTC patients to provide references for radiation protection showed that the 24-h iodine uptake rate was the only significant factor associated with radioiodine clearance. Expand
MicroRNA aberrances in head and neck cancer: pathogenetic and clinical significance
A number of pathways that become disregulated by aberrant miRNAs have been identified specifically for HNSCC and analysis of these networks and their therapeutic interception might facilitate the prediction of disease status and help with the design of therapeutic trials. Expand


Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients.
Success rates are equal to or better than those reported with empiric methods of 131I administration and the individualized treatment planning selectively allocates hospitalization and higher exposures to 131I to those patients who require them. Expand
An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan.
Of 267 patients with radioiodine uptake confined to the thyroid bed, 233 had ablation from the first dose of I-131 ranging from 100 to greater than 200 mCi, with the higher the percent uptake, the more difficult it was to achieve ablation. Expand
Effective half-life of 131I in thyroid cancer patients.
Analysis of a database of more than 250 administrations of 131I for thyroid cancer shows a median effective half-life of at least 14 h, with substantial variation, which challenges some long-used assumptions regarding iodine excretion in this patient population. Expand
[A study on the isolation period of patients with metastatic thyroid cancer treated by 131I according to a new guideline].
The 3-day isolation is sufficient for the patients administered 3.7 GBq of Na131I and there was a significant correlation between the predicted value of residual radioactivity in the body (y' MBq) and the external exposure dose (x' microSv/h); y' = 20.8x' + 31.5, r = 0.98, p < 0.001, n = 77. Expand
Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer.
Evaluated responses to therapeutic irradiation with 131I in 76 patients with thyroid adenocarcinoma found patients with metastases that persisted after 131I therapy tended to have more advanced disease and received significantly lower radiation doses per millicurie of administered 131I than did persons whose lesions responded to treatment. Expand
Radioactive iodine (131I) therapy for differentiated thyroid cancer in Japan: current issues with historical review and future perspective
In this review, this therapy is looked at through several lenses, including historical, cultural, medical, and socio-economic points of view, to lead to the resolution of this complicated situation in Japan. Expand
Diuretic-enhanced I-131 clearance after ablation therapy for differentiated thyroid cancer.
Administration of diuretics can improve I-131 clearance in patients with thyroid cancer and slow clearance, reducing the radiation burden and shortening the hospital stay. Expand
Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma.
In the opinion, there has not been any side effect to date which would contraindicate the continued use and evaluation of the BEL dosimetry approach and the immediate and intermediate side effects after the initial 15 therapies in ten patients are reviewed. Expand
Hospital discharge of patients with thyroid carcinoma treated with 131I.
The type of measurements performed in this study reveals more realistic doses for the treatment of thyroid carcinoma with 131I, especially for countries with more restrictive dose limits. Expand
131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients
In patients who undergo thyroid hormone withdrawal, the longer mean effective half-life is mainly due to delayed renal excretion of 131I and results in dose estimates higher than the data in report 53 of the International Commission on Radiological Protection, which were obtained from healthy, euthyroid subjects. Expand